Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.26 +5.2%	$6.01	$3.93 ▼ $7.32	$320.24M	1.51	1.09 million shs	1.03 million shs
CABA Cabaletta Bio	$1.69 +3.7%	$1.76	$0.99 ▼ $7.88	$85.76M	2.7	1.61 million shs	730,704 shs
GOSS Gossamer Bio	$1.67 +15.2%	$1.23	$0.66 ▼ $1.71	$379.59M	1.86	1.46 million shs	4.19 million shs
IVA Inventiva	$3.31 -0.6%	$3.31	$1.53 ▼ $4.05	$316.64M	0.73	64,258 shs	6,156 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+0.51%	+1.88%	-3.41%	+22.68%	+10.39%
CABA Cabaletta Bio	-3.55%	+7.95%	-18.09%	+50.93%	-79.13%
GOSS Gossamer Bio	-5.23%	+14.17%	+16.94%	+74.68%	+22.88%
IVA Inventiva	-6.33%	-6.33%	-4.96%	-2.08%	+21.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.724 of 5 stars	3.5	1.0	4.5	1.8	2.5	0.0
CABA Cabaletta Bio	2.7456 of 5 stars	3.5	4.0	0.0	2.5	0.8	0.6
GOSS Gossamer Bio	3.7713 of 5 stars	3.5	1.0	4.7	2.7	1.7	0.0
IVA Inventiva	3.163 of 5 stars	3.4	5.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	207.51% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	753.76% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	394.01% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	214.20% Upside

Current Analyst Ratings Breakdown

Latest CABA, IVA, ABEO, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
4/30/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	$1.01 per share	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
GOSS Gossamer Bio	$114.70M	3.31	N/A	N/A	$0.13 per share	12.85
IVA Inventiva	$9.95M	31.82	N/A	N/A	($1.21) per share	-2.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)

Latest CABA, IVA, ABEO, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
CABA Cabaletta Bio	N/A	3.96	3.96
GOSS Gossamer Bio	6.70	5.71	5.71
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CABA Cabaletta Bio	N/A
GOSS Gossamer Bio	81.23%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	5.40%
CABA Cabaletta Bio	11.25%
GOSS Gossamer Bio	6.70%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	48.40 million	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

CABA, IVA, ABEO, and GOSS Headlines

Recent News About These Companies

Inventiva appoints new R&D president and regulatory affairs executive

July 11, 2025 | investing.com

Inventiva names Jason Campagna as President of R&D and Chief Medical ...

July 11, 2025 | finance.yahoo.com

Inventiva Strengthens Leadership Team Ahead of Key MASH Drug Milestones

July 10, 2025 | yahoo.com

Inventiva reshuffles leadership as it pushes lanifibranor closer to approval

July 10, 2025 | thepharmaletter.comT

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

July 9, 2025 | globenewswire.com

INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ

July 8, 2025 | finanznachrichten.de

Inventiva receives $10 million milestone payment from CTTQ

July 7, 2025 | globenewswire.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients ... - The Manila Times

July 4, 2025 | manilatimes.netM

Inventiva (NASDAQ:IVA) Trading 2.7% Higher - Here's Why

July 4, 2025 | marketbeat.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

July 2, 2025 | globenewswire.com

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

June 24, 2025 | msn.com

Inventiva appoints former Calliditas CEO to board of directors

June 11, 2025 | uk.investing.com

INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 11, 2025 | finanznachrichten.de

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 10, 2025 | manilatimes.netM

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

June 3, 2025 | zacks.com

INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | finanznachrichten.de

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | globenewswire.com

Inventiva S.A. reports Q1 results

May 23, 2025 | seekingalpha.com

INVENTIVA: Inventiva reports 2025 First Quarter Financial Information

May 23, 2025 | finanznachrichten.de

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom
Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
By Nathan Reiff | June 18, 2025
View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
Lululemon Slips as Rivals Rally: 3 Stocks to Watch
By Dan Schmidt | June 30, 2025
View Lululemon Slips as Rivals Rally: 3 Stocks to Watch
AES Gains 20% as Private Equity Eyes AI Hyperscale Energy Player
By Leo Miller | July 14, 2025
View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy Player

CABA, IVA, ABEO, and GOSS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.26 +0.31 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$6.22 -0.04 (-0.72%)

As of 05:24 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Cabaletta Bio NASDAQ:CABA

$1.69 +0.06 (+3.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 -0.01 (-0.59%)

As of 05:40 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Gossamer Bio NASDAQ:GOSS

$1.67 +0.22 (+15.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+0.90%)

As of 05:39 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Inventiva NASDAQ:IVA

$3.32 -0.01 (-0.18%)

As of 03:57 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time